Articles By Jack Cush, MD
AS vs. SpA Responses with Combination Treatment
Patients in a large Swedish registry with ankylosing spondylitis (AS) and spondyloarthritis (SpA) who started a TNF inhibitor were followed for comedication use and TNF inhibitor survival.
Read Article
Comorbidities Abound in Fibromyalgia
Fibromyalgia is a highly prevalent disorder with different studies and populations showing a prevalence of 2.1% to 6.4% in the general population. A retrospective review from Olmstead county revealed that among 1
Read Article
The Prevalence of Ankylosing Spondylitis
A retrospective study of the national register in Sweden identified a total of 11,030 cases with an ankylosing spondylitis (AS) diagnosis (as of 2009) were identified in the National Patient Register, giving a point prevalence of 0.18% in 2009. Men had a higher prevalence of ankylo
Read ArticleHot Stuff Part IV: Cardiovascular Outcomes and Vasculitis
The last in a four-part series from the CCF's Biologic Therapies Summit, we examine how to reduce CV risks in practice plus the current status of vasulitis management and the role biologics may play.
Read Article
Communication is the Best Medicine
Patients rate communication as one of the most important factors in choosing and sticking with a physician. The end product in at least 2/3 of visits is the prescription, yet prescription adherence is substandard in half of our patients. The key is communication.
Read Article
The Risk of Listeriosis in RA
In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.
Read Article
House Bill Threatens CME Exemption from Sunshine Act Reporting
Current Sunshine Act disclosures do not apply to CME certified educational activities for either the participants or the presenters. CMS has debated and waffled on whether companies would be required to report payments to doctors who speak at, or attend, CME seminars.
Read Article
Is There a Standout When Comparing Novel Therapies?
Randomized clinical trials are needed to show efficacy and safety, and are needed to back up the claims and indications for a particular drug. The issue of treatment choice has become challenging, especially when choosing to start or augment therapy.
Read ArticleHot Stuff Part III: Zoster and Biologics: Special Considerations
Part III covers talks on H. Zoster, biologics and SpA.
Read Article
